Related Experiment Videos
[Clinico-laboratory basis for the endolymphatic use of beta-lactam antibiotics in pulmonology]
Abstract:
Clinical efficacy and effect of cefuroxime, claforan and pentrexyl used endolymphatically were studied in 85 patients with acute abscess forming and persisting pneumonia. Previous routine antibiotic therapy in these patients was little effective. Administration of the antibiotics into the peripheral lymph nodes provided blocking of the lymphagenic pathway for the infection due to high levels in the lymphatic system. Endolymphatic use of cefuroxime and claforan resulted in a significant improvement of the functions of the T- and B-immunity systems and the indices of natural resistance. The levels of the autoimmune reactions and sensitization to the bacterial antigens decreased. Endolymphatic use of cefuroxime and claforan once every 3 days provided recovery of 9 2.8 per cent of the patients, the treatment periods being decreased 2.5--3 times. Intravenous administration of the drugs according to the routine schemes, endolymphatic use of pentrexyl (5 g once every 3 days) and endolymphatic administration of cefuroxime in a single dose followed by intravenous therapy was less effective. The efficacy of pentrexyl increased, when it was used endolymphatically in combination with lysozyme. Endolymphatic use of claforan in doses of 2--3 g once every 3 days (3--4 infusions during the treatment course) was most effective.
Insights
Endolymphatic administration of cefuroxime and claforan antibiotics significantly improved immunity and resistance in pneumonia patients, leading to faster recovery. This method proved more effective than traditional intravenous antibiotic therapy.
Area of Science:
- Infectious Diseases
- Immunology
- Pharmacology
Background:
- Acute abscess-forming and persisting pneumonia often shows limited response to conventional antibiotic treatments.
- Lymphatic system plays a crucial role in the spread of infection, making it a potential target for therapeutic intervention.
Purpose of the Study:
- To evaluate the clinical efficacy of endolymphatic administration of cefuroxime, claforan, and pentrexyl in patients with refractory pneumonia.
- To assess the impact of endolymphatic antibiotic therapy on immune system functions and natural resistance indices.
Main Methods:
- A study involving 85 patients with acute abscess-forming and persisting pneumonia.
- Comparison of endolymphatic antibiotic administration (cefuroxime, claforan, pentrexyl) versus traditional intravenous therapy.
- Assessment of T- and B-immunity systems, natural resistance, autoimmune reactions, and bacterial antigen sensitization.
Main Results:
- Endolymphatic cefuroxime and claforan significantly improved T- and B-immunity and natural resistance, while decreasing autoimmune reactions and sensitization.
- Recovery rates reached 92.8% with endolymphatic cefuroxime and claforan, reducing treatment duration by 2.5-3 times.
- Endolymphatic pentrexyl, especially combined with lysozyme, and endolymphatic cefuroxime followed by IV therapy showed less efficacy compared to combined endolymphatic cefuroxime/claforan.
Conclusions:
- Endolymphatic administration of cefuroxime and claforan is a highly effective treatment for acute abscess-forming and persisting pneumonia, offering improved immune response and faster recovery.
- This route of administration targets the lymphatic pathway of infection, leading to superior clinical outcomes compared to standard intravenous methods.
- Optimal regimen involves endolymphatic claforan (2-3g every 3 days) for maximum efficacy in treating severe pneumonia.